# **BELL POTTER**

Analyst Jonathan Snape 613 9235 1601

Authorisation Joseph House 613 9235 1624

### Recommendation Hold (unchanged) Price A\$7.11 Target (12 months) A\$7.25 (previously A\$6.00)


#### Sector

Food Beverage and Tobacco

Expected Return	
Capital growth	2.0%
Dividend yield	2.5%
Total expected return	4.5%
<b>Company Data &amp; Ratios</b>	
Enterprise value	A\$4,318m
Market cap	A\$5,148m
Issued capital	724.0m
Free float	100%
Avg. daily val. (52wk)	A\$18.7m
12 month price range	A\$4.73-7.37

Price Performance										
	(1m)	(3m)	(12m)							
Price (A\$)	5.62	4.82	5.26							
Absolute (%)	25.80	46.68	34.41							
Rel market (%)	22.40	43.66	22.62							

#### **Absolute Price**



BELL POTTER SECURITIES LIMITED ABN 25 006 390 772

ABN 25 006 390 772 AFSL 243480

SOURCE: IRESS

The a2 Milk Co (A2M)

Afterlife

### 1H25 Results at a glance

A2M reported 1H25 underlying NPAT broadly line with our expectations at NZ\$91.7m. Key operating statistics of the result included:

**Operating results:** Revenue of NZ\$893.8m was up +10% YOY (vs. BPe NZ\$873.4m). EBITDA of NZ\$118.9m was up +5% YOY (vs BPe of NZ\$119.1m). EBITDA ex-MVM was NZ\$130.8m (vs. BPe of NZ\$127.2m). Underlying NPAT of NZ\$91.7m was up +8% YOY (vs. BPe of NZ\$90.9m).

**Infant formula drivers:** R12M market shares in China offline was flat at 3.5% (FY24 at 3.5%), down in CBEC at 19.1% (FY24 20.5% & 1H24 21.4%) and down in O2O/Daigou at 17.9% (FY24 19.7% & 1H24 20.5%). China direct IMF revenues were up +11.0% YOY to NZ\$563.4m (vs. BPe NZ\$545m) and represented 93% of total 1H25 IMF sales (91% in 1H24). Marketing expenditure of NZ\$145.9m (vs. BPe of NZ\$136.6m and 1H24 of \$136.7m).

**Cashflow and balance sheet:** A lease adjusted operating cashflow of NZ\$75.9m compares to NZ\$60.1m in 1H24. Net cash exited the period at NZ\$947.4m and compares to FY24 at NZ\$902.7m.

**FY25e outlook:** Key outlook comments include: (1) FY25e revenue guidance of lowto-mid double-digit YOY growth (vs mid-to-high-single digit revenue growth previously); (2) FY25e EBITDA margins are expected to be slightly up vs. FY24 levels; (3) FY25e operating cash conversion to be 90% reflecting SM1 settlement payments.

NPAT changes are +10% in FY25e, +9% in FY26e and +8% in FY27e. Our target price is A\$7.25ps (prev. A\$6.00ps) following these changes and a lower WACC hurdle.

### Investment view: Hold rating unchanged

Our Hold rating is unchanged. 1H25 was a good result and the upgrade to guidance a little stronger than we would have expected when FX movements were allowed for (we had been expecting a +200-300bp tailwind from FX and GDT moves post Nov'24). The forward growth is reasonable, but at 17.6x FY25e EBITDA, it's a big premium to the sector (Dairy peers at 12.2x & IMF peers at 8.2x) and A2M's T3Yaverage (of 14.5x).

Year end June	2024	2025e	2026e	2027e
Sales (NZ\$m)	1675.5	1885.3	2001.6	2032.2
EBITDA (NZ\$m)	234.3	272.5	296.7	301.2
NPAT (adjusted) (NZ\$m)	167.6	200.1	218.1	223.4
NPAT (reported) (NZ\$m)	109.7	200.1	218.1	223.4
EPS (adjusted) (NZ cps)	23.1	27.5	30.0	30.7
EPS growth (%)	9.2	19.2	8.9	2.4
PER (x)	34.2	28.6	26.3	25.7
FCF Yield (%)	5.0	2.8	1.8	1.7
EV/EBITDA (x)	20.4	17.6	16.1	15.9
Dividend (NZ Cps)	0.0	17.5	19.5	21.5
Franking (%)	0.0	100.0	100.0	100.0
Yield (%)	0.0	2.5	2.7	3.0
ROE (%)	13.3	15.2	15.7	15.4

DISCLAIMER: THIS REPORT MUST BE READ WITH THE DISCLAIMER ON PAGE 9 THAT FORMS PART OF IT.

# 1H25 result at a glance

**Result:** A2M reported a 2% stronger than expected revenue outcome largely driven by the performance of the fresh dairy and CBEC IMF channels. EBITDA was broadly in line with our expectations at NZ\$118.9m (vs. BPe of NZ\$119.1m) with higher net interest driving a 1% better outcome at NPAT. A lease adjusted operating cashflow of NZ\$75.9m compares to NZ\$60.1m in 1H24 and net cash exited the period at NZ\$947.4m (vs FY24 at NZ\$902.7m). A 1H25 DPS of NZ8.5¢ (vs. BPe 7.5¢), reflected a payout ratio of 67%.

Profit & Loss	2019	1H20	2H20	2020	1H21	2H21	2021	1H22	2H22	2022	1H23	2H23	2023	1H24	2H24	2024	1H25	1H25e	YOY
Australia/NZ	842.7	460.2	505.5	965.7	317.2	242.5	559.7	283.3	249.5	532.7	213.7	158.0	371.7	162.2	155.1	317.3	157.7	160.0	-3%
China	405.7	317.2	382.2	699.4	326.0	257.4	583.4	306.3	420.2	726.5	471.6	530.6	1,002.2	549.5	593.6	1,143.1	614.2	587.7	12%
US & UK	56.1	28.0	38.1	66.1	34.2	29.4	63.6	32.4	50.2	82.7	52.4	52.6	105.1	56.9	56.7	113.7	64.5	58.3	13%
Processing								38.6	70.3	108.9	62.9	83.3	146.2	51.5	84.9	136.4	73.1	75.4	42%
Corporate and other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	(4.5)	(17.2)	(15.0)	(32.3)	(8.0)	(27.0)	(35.0)	(15.7)	(8.0)	96%
Revenue	1,304.5	805.3	925.8	1,731.1	677.4	529.4	1,206.7	660.5	790.2	1,446.2	783.3	809.5	1,592.9	812.1	863.3	1,675.5	893.8	873.4	10%
Australia/NZ	388.2	227.9	237.7	465.6	117.5	31.4	148.8	96.2	77.0	173.2	62.0	31.5	93.5	34.8	28.2	63.0	29.5	28.1	-15%
China	123.9	117.5	107.4	224.9	94.4	(18.8)	75.6	59.4	85.7	145.1	111.5	142.6	254.1	135.9	154.2	290.1	148.0	148.8	9%
US & UK	(39.5)	(30.0)	(20.5)	(50.5)	(11.6)	(21.9)	(33.5)	(16.4)	(20.2)	(36.7)	(12.2)	(11.1)	(23.3)	(8.3)	(7.1)	(15.5)	(4.9)	(5.6)	-42%
Processing								(10.0)	(8.8)	(18.8)	(13.4)	(13.1)	(26.5)	(15.3)	(5.2)	(20.5)	(11.9)	(8.1)	-22%
Corporate & Other	(58.9)	(48.9)	(39.0)	(87.9)	(21.7)	(45.8)	(67.5)	(31.6)	(35.0)	(66.6)	(40.1)	(38.4)	(78.5)	(33.8)	(49.0)	(82.8)	(41.9)	(44.1)	24%
Associates	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a.
EBITDA	413.7	266.5	285.6	552.0	178.5	(55.1)	123.4	97.6	98.6	196.2	107.8	111.5	219.3	113.2	121.1	234.3	118.9	119.1	5%
EBITDA Margin (%)	31.7%	33.1%	30.8%	31.9%	26.4%	-10.4%	10.2%	14.8%	12.5%	13.6%	13.8%	13.8%	13.8%	13.9%	14.0%	14.0%	13.3%	13.6%	-5%
Depreciation & Amortisation	(2.2)	(1.8)	(2.6)	(4.4)	(3.2)	(4.3)	(7.5)	(8.2)	(10.7)	(18.9)	(9.0)	(9.2)	(18.2)	(8.9)	(23.3)	(32.2)	(15.0)	(13.8)	69%
EBIT	411.6	264.7	282.9	547.6	175.3	(59.3)	116.0	89.3	87.9	177.3	98.8	102.3	201.1	104.4	97.8	202.1	103.9	105.2	0%
EBIT Margin (%)	31.5%	0.0%	0.0%	31.6%	25.9%	-11.2%	9.6%	13.5%	11.1%	12.3%	12.6%	12.6%	12.6%	12.8%	11.3%	12.1%	11.6%	12.1%	-10%
Net Interest Income	4.2	2.9	2.9	5.7	1.7	1.5	3.3	1.1	3.0	4.1	9.9	11.9	21.8	16.6	19.4	36.0	23.4	20.0	41%
Pre-tax profit	415.7	267.6	285.8	553.4	177.1	(57.8)	119.3	90.5	90.9	181.4	108.7	114.2	222.9	120.9	117.2	238.1	127.3	125.2	5%
Tax	(128.0)	(79.4)	(85.8)	(165.2)	(57.0)	(37.8)	(38.6)	(34.4)	(32.3)	(66.6)	(40.2)	(37.8)	(78.0)	(42.3)	(41.9)	(84.3)	(43.3)	(40.3)	2%
Minorities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	(32.3)	7.9	5.3	5.5	10.8	6.7	7.0	(04.3)	7.7	6.0	16%
Underving NPAT	288.0	188.2	200.0	388.1	120.0	(39.4)	80.7	59.6	63.0	122.6	73.8	81.9	155.6	85.3	82.3	167.6	91.7	90.9	8%
Non-recurring items (post-tax)	(66.7)	(13.9)	(41.6)	(55.5)	(67.4)	(66.1)	(133.5)	(7.0)	0.0	(24.5)	22.4	(80.7)	(58.3)	(33.8)	(24.1)	(57.9)	0.0	0.0	n.a.
Reported NPAT	221.3	174.3	158.4	332.6	52.6	(105.5)	(52.9)	52.7	63.0	98.2	96.2	1.2	97.4	51.5	58.2	109.7	91.7	90.9	78%
Balance Sheet and cashflow	2019	1H20	2H20	2020	1H21	2H21	2021	1H22	2H22	2022	1H23	2H23	2023	1H24	2H24	2024	1H25	1H25	YOY
																		1HZ0	TUT
Working Capital (\$m)	50.6	56.7	(7.6)	(7.6)	116.5	(61.0)	(61.0)	(53.4)	(98.0)	(98.0)	7.5	5.1 0.3%	5.1	36.2 4.5%	(37.3)	(37.3)	(40.5)		
Working Capital/Sales - T12M (%)	3.9%	7.0%	-0.8%	-0.4%	17.2%	-11.5%	-5.1%	-8.1%	-6.8%	-6.8%	1.0%		0.3%			-2.2%	-4.5%		
Net Debt (Cash) (\$m)	(464.8)	(618.4)	(854.2)	(854.2)	(774.6)	(875.2)	(875.2)	(667.2)	(763.0)	(763.0)	(655.4)	(700.7)	(700.7)	(735.1)	(902.7)	(902.7)	(947.4)		
Operating cashflow (\$m)	289.1	159.9	265.8	425.6	(10.8)	77.0	66.2	96.4	103.3	199.7	(5.1)	112.8	107.7	60.1	190.9	250.9	75.9		
Operating cash realistaion (%)	100%	84%	131%	108%	-9%	-219%	75%	109%	152%	141%	-7%	80%	62%	73%	210%	126%	44%		
IMF Performance stats	2019	1H20	2H20	2020	1H21	2H21	2021	1H22	2H22	2022	1H23	2H23	2023	1H24	2H24	2024	1H25	1H25e	YOY
PRC Revenue (NZ\$m)	167.8	146.7	191.0	337.7	213.1	176.8	389.9	188.7	248.9	437.6	270.7	288.6	559.3	299.0	313.3	612.3	305.0	320.0	2%
CBEC Revenue (NZ\$m)	237.8	160.5	180.6	341.1	103.5	65.4	168.9	102.4	153.4	255.8	175.6	210.6	386.2	210.5	237.3	447.8	258.4	225.0	23%
China Direct Revenue (NZ\$m)	405.7	307.2	371.6	678.8	316.6	242.2	558.8	291.1	402.3	693.4	446.3	499.2	945.6	509.5	550.7	1,060.2	563.4	545.0	11%
ANZ EL US EL	658.1	352.0	393.0	745.1	209.5	147.5	357.0	179.9	148.9	328.8	109.4	53.1	162.5	54.6 0.2	43.9 0.2	98.5 0.4	40.5 0.8	49.2 1.2	-26% 367%
Total IMF revenue	1.063.8	659.2	764.7	1.423.9	526.1	389.7	915.8	471.0	551.2	1.022.2	555.7	552.4	1,108.1	0.2 564.3	605.4	1.159.1	604.7	595.3	307% 7%
	1,063.8	059.2 10%	12%	1,423.9	520.1 10%	389.7 19%	915.8 14%	471.0 14%	551.Z 17%	1,022.2	555.7 17%	552.4 15%	1,108.1	304.3 17%	005.4 17%	1,159.1 17%	604.7 16%	595.3 16%	1 70
Marketing to sales (%) Infant Formula share of sales (%)	82%	82%	83%	82%	78%		14% 76%	14% 71%	70%	71%	71%	15% 68%	70%	69%	70%	69%	10% 68%	68%	
						74%												08%	
Gross Margin (%)	55%	57%	55%	56%	50%	32%	42%	46%	45%	46%	48%	45%	46%	47%	45%	46%	45%		
Total Share													5.9%	6.4%	7.3%	7.3%	7.7%		
CL share													3.9%	4.1%	4.9%	4.9%	5.3%		
EL share						20.2%	20.2%	20.0%	19.0%	19.0%	17.9%	19.1%	19.1%	20.6%	20.2%	20.2%	19.1%		

SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES

**Key outlook comments include:** (1) FY25e revenue guidance of low double digit-to-mid double digit growth (vs mid-to-high-single digit revenue growth previously); (2) FY25e EBITDA margins are expected to be slightly up vs. FY24 levels; (3) FY25e operating cash conversion to be 90% reflecting SM1 settlement payments. Element of the guidance upgrade are stronger demand for English label IMF, increased US liquid milk sales, movements in the NZD and high GDT ingredient pricing. We had estimated the latter two would add 200-300bp to the top line.

There have been Three major changes in our forecasts, being: (1) a shift in growth from PRC to English label which carries a net margin gain; (2) a material reduction in NZD assumptions against the USD, CNY and AUD. The latter has a favourable impact on FY25-27e revenues and an unfavourable impact on COGS in FY26-27e; and (3) a reduction in births in CY25-26e following a softer than expected marriage rate in CY24 (movements in births have a >90% correlation to movements in marriages in the preceding year).

## **BELL POTTER**

**Market share:** Overall China market share (R12M) was up +40bp relative to 2H24, largely reflecting a shift in purchase channels towards online. Offline market share was static at 3.5%, domestic online up +20bp to 4.1% and online English label down 90bp to 19.1%.





Figure 4 - A2M IMF market share data

Market share statistics	2019	1H20	2H20	2020	1H21	2H21	2021	1H22	2H22	2022	1H23	2H23	2023	1H24	2H24	2024	1H25
Offline stockists	16,400	18,300	19,100	19,100	22,000	22,800	22,800	24,600	26,500	26,500	26,800	25,900	25,900	25,900	29,000	29,000	29,80
Numeric distribution (%)							21%	23%	25%	25%	26%	27%	27%	28%	26%	26%	
Weighted distribution (%)							40%	44%	44%	44%	47%	47%	47%	48%	44%	44%	
Total PRC Market share (%)															4.9%	4.9%	5.3%
R12M MBS market share (%)		1.4%	1.7%	1.7%	2.1%	2.2%	2.2%	2.5%	3.0%	3.0%	3.2%	3.4%	3.4%	3.5%	3.5%	3.5%	3.5%
Key & A cities						5.7%	5.7%	6.3%	7.1%	7.1%	7.4%	7.5%	7.5%	7.4%	6.8%	6.8%	6.7%
BCD cities						1.6%	1.6%	1.9%	2.3%	2.3%	2.5%	2.7%	2.7%	2.9%	3.0%	3.0%	3.0%
R12M Domestic online share (%)		1.3%	1.6%	1.9%	2.0%	2.0%	2.0%	2.1%	2.5%	2.5%	3.0%	3.3%	3.3%	3.6%	3.9%	3.9%	4.1%
R12M English label share (%)						20.2%	20.2%	20.0%	19.0%	19.0%	17.9%	19.1%	19.1%	20.6%	20.2%	20.2%	19.1%
CBEC	19.0%	20.6%	21.7%	21.7%	22.2%	21.1%	21.1%	19.5%	19.4%	19.4%	21.6%	22.6%	22.6%	21.4%	20.5%	20.5%	20.2%
O2O/Daigou					23.5%	21.2%	21.2%	19.7%	19.5%	19.5%	19.8%	20.7%	20.5%	20.5%	19.7%	19.7%	17.99


SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES

# A2M variable earnings drivers


**Australian Shipments:** Export activity ex-Australia into China looks to have bottomed, demonstrating modest growth from the lows. Since A2M inventory issues this dataset has a 94% correlation to A2M Australian IMF sales.



**China activity levels:** PRC label sales correlates closely to Direct China shipment values ex-CHC (at 92%) and CBEC correlates to HK + China direct shipment values (at 89%).



**Ingredient input costs:** IMF commodity constituents have lifted in recent months. US Class 1 milk prices YTD are up +14% YOY.



## **BÉLL POTTER**

# A2M Overview

### COMPANY DESCRIPTION

The a2 Milk Company (A2M) is in the business of producing, marketing and selling branded dairy and infant milk formula (IMF) products in Australia, New Zealand, China, US and UK. A2M branded milk contains only A2 Protein rather than both A1 and A2 proteins which are found in Regular Cows' Milk. The business model of A2M is to focus on consumer facing products with a target on the functional food markets where a premium can be generated.

### TARGET PRICE

Our target price for A2M is A\$7.25ps and derived utilising our ROIC based methodology. In deriving our target price we have utilised: (1) FY25e ROIC of 75% lifting to 88% in FY26e; (2) a pre-tax WACC of 10.2%; and (3) AUDNZD cross rate consistent with the spot. To this we incorporate a value for A2M's holding in SM1 at market.

### RISKS

A2M is a high growth FMCG business with exposures to an agricultural supply chain. Risks associated in an investment in A2M include but are not isolated to:

**COVID-19:** The substantial impact of COVID-19 on the global and domestic economies is creating enormous volatility and uncertainty in global share markets. The forecasts in the report may be subjected to significant changes if this situation continues for an extended period of time.

**Scientific risk**: The A2M brand proposition is built primarily on the potential digestive wellbeing benefits of A1 Protein Free milk products compared to Regular Cows' Milk products which contain both A1 Protein and A2 Protein. There is the risk of research or information being published that diminishes or rejects the scientific arguments or consumers' experiences as to the benefits of the consumption of A1 Protein Free dairy products. As a result, the A2M brand may lose its differentiated position and it may become difficult for A2M to continue to position its products as premium products sold at a premium price.

**Intellectual Property:** A2M's business relies in part on its intellectual property portfolio, including brands and trademarks, patents, proprietary processes and know-how. Some forms of registered intellectual property, including patents, are of fixed duration and will expire over time. As any of A2M's registered intellectual property expires, or if it is invalidated or removed from intellectual property registers, this will adversely impact on A2M's ability to claim and enforce exclusive rights in such intellectual property. Because of the importance of its intellectual property, A2M may also need to defend its intellectual property or take action against third parties that infringe or claim rights in its intellectual property. Such action may include litigation, which may be protracted and expensive, and which may result in negative publicity.

**Emergence of new competition:** A2M's business model relies on A2M branded products being differentiated from other dairy products in each market in which it operates because they consist of, or are made using, A1 Protein Free milk. There is a risk that a competitor or competitors may launch A1 Protein Free milk products, and this risk may increase over time as A2M patents expire. There is also a risk that competitors may develop branding that creates confusion between a2MC branded products and Regular Cows' Milk products or otherwise reduces the perception of A2M branded products as differentiated A1 Protein Free milk products as differentiated A1 Protein Free milk products.

**Supply chain disruption:** A2M's business model and supply chain are dependent on contractual arrangements with third parties which provide essential processing, production

## **BELL POTTER**

or distribution functions for A2M branded products globally. There is the risk that the operations of one or more third parties change in a material and adverse way or that one or more third parties could reduce their support for the A2M brand. This could reduce A2M's ability to maintain supply to its customers in the short to medium term and reduce its ability to maintain its position in existing markets or enter new markets. This may also necessitate the need for A2M to invest in manufacturing capacity that would likely be returns dilutionary.

**Brand risk:** In common with many other food companies, there is a risk that raw materials may deteriorate or that products may become contaminated, tampered with, adulterated or otherwise unsafe or unfit for sale or consumption within the supply chain due to various factors, including human error and equipment failure. Potential adverse consequences for A2M include regulatory penalties, termination of distribution arrangements, liability associated with adverse health effects on consumers, product recall and disposal costs, loss of stock, delay in supply and financial costs.

**Regulatory risk:** A2M and its strategic suppliers and contractors require certain licences, approvals and consents in order to conduct their businesses. There is a risk that any such licences, approvals or consents that are material to a2MC in operating its business will not be renewed or will be renewed on more restrictive or onerous terms, or in limited circumstances, revoked.

**China regulatory risk:** At this stage we are projecting no material change in China C2C law changes which would likely have a detrimental impact on the level of sales in the Australian IMF business, but following a transition would be more than mitigated by faster growth in the China business where gross margins are higher than those achieved in Australia. As such while we are cognisant that a change in Chinese C2C trading regulations can impact near term earnings, we don't necessarily view this as detrimental to the company's longer-term growth trajectory.

**Key personnel risk:** A2M's performance is dependent on the ability of its senior executives and key personnel to manage and grow its business. Continuity and retention of senior executives and key personnel are important for the ongoing implementation of A2M's strategy.

**Execution risk:** Part of our optimism centres around management's ability to generate a profitable return in the US and UK fresh dairy markets. Failure to execute this strategy may impact stock performance and its ability to realise our target price.

### The a2 Milk Co as at 17 February 2025

Recommendation	Hold
Price	A\$7.11
Target (12 months)	A\$7.25

Hold \$7.11

\$7.25

70.0%

3.0%

Rating

Share price (A\$ps)

Target price (A\$ps)

Payout (%)

Yield (%)

Table 1	- Financia	al summarv

Year end June	2020	2021	2022	2023	2024	2025e	2026e	2027e
Profit & Loss (NZ\$m)								
Sales revenue	1,731.1	1,206.7	1,446.2	1,592.9	1,675.5	1,885.3	2,001.6	2,032.2
Change	32.7%	-30.3%	19.8%	10.1%	5.2%	12.5%	6.2%	1.5%
EBITDA	552.0	123.4	196.2	219.3	234.3	272.5	296.7	301.2
Deprec. & amort.	(4.4)	(7.5)	(18.9)	(18.2)	(32.2)	(30.2)	(27.2)	(29.2)
EBIT	547.6	116.0	177.3	201.1	202.1	242.3	269.5	272.0
Interest expense	5.7	3.3	4.1	21.8	36.0	43.0	38.7	41.6
Pre-tax profit	553.4	119.3	181.4	222.9	238.1	285.4	308.2	313.5
Tax expense	(165.2)	(38.6)	(66.6)	(78.0)	(84.3)	(95.1)	(97.8)	(97.9)
tax rate	30%	32%	37%	35%	35%	33%	32%	31%
Minorities	0.0	0.0	7.9	10.8	13.7	9.8	7.6	7.8
Net Profit	388.1	80.7	122.6	155.6	167.6	200.1	218.1	223.4
Abs. & extras.	(55.5)	(133.5)	(24.5)	(58.3)	(57.9)	0.0	0.0	0.0
Reported Profit	332.6	(52.9)	98.2	97.4	109.7	200.1	218.1	223.4

Cashflow (NZ\$m)								
EBITDA	552.0	123.4	196.2	219.3	234.3	272.5	296.7	301.2
Net Interest Expense	5.7	3.3	3.0	18.8	36.9	43.0	38.7	41.6
Tax Paid	(197.9)	(97.8)	(23.0)	(34.9)	(75.6)	(89.7)	(96.4)	(97.8)
Change in Wkg Capital	58.2	53.4	37.0	(103.1)	42.4	(11.6)	1.6	0.4
Other	7.6	(16.2)	(13.4)	7.7	12.9	0.0	0.0	0.0
Operating Cash Flow	425.6	66.2	199.7	107.7	250.9	214.3	240.6	245.3
Capex	(7.2)	(7.3)	(5.2)	(10.4)	(13.5)	(20.3)	(20.3)	(15.3)
Dividend paid	0.0	0.0	0.0	0.0	0.0	(61.5)	(133.9)	(148.4)
Free Cash Flow	418.4	58.9	194.5	97.3	237.4	132.4	86.3	81.6
Acquisitions	(21.9)	(57.1)	(214.8)	(3.5)	(16.6)	(37.5)	0.0	0.0
Disposals	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Share issues	0.0	2.2	(13.3)	(149.1)	0.0	0.0	0.0	0.0
Other	(7.2)	17.0	(78.6)	(7.0)	(18.8)	0.0	0.0	0.0
(Inc.) /dec. in net debt	389.4	21.0	(112.2)	(62.3)	202.0	94.9	86.3	81.6

Palanaa Shaat (N7¢m)								
Balance Sheet (NZ\$m) Cash & near cash	854.2	875.2	887.3	802.2	968.9	1,063.9	1,150.2	1,231.7
Receivables	70.7	65.3	83.5	79.2	78.1	94.3	100.1	101.6
Inventories	147.3	112.2	140.0	193.4	179.6	188.5	200.2	203.2
Other	56.3	44.3	60.4	47.2	61.3	67.9	71.5	72.5
Current assets	1,128.5	1,096.9	1,171.2	1,122.1	1,287.9	1,414.5	1,521.9	1,609.0
Fixed assets	30.4	17.2	240.5	245.2	231.4	219.4	209.4	196.8
Intangibles	13.6	15.1	109.3	108.4	111.1	108.0	107.5	190.0
Other	280.8	242.8	194.7	136.0	104.4	114.4	107.5	134.4
Non current assets	324.8	242.0	544.6	489.6	446.9	441.8	441.4	438.2
Total assets	1.453.3	1.372.0	1.715.9	1.611.7	1.734.9	1.856.3	1.963.3	2.047.2
Creditors	281.9	266.3	376.1	313.2	347.6	367.6	390.3	396.3
	201.9	200.5	43.9	19.2	5.6	5.6	590.5 5.6	5.6
Borrowings	•••	•.•			•.•		•••	
Other	23.5	8.4	20.2	46.8	63.6	101.4	116.5	134.5
Current liabilities	305.4	274.7	440.2	379.2	416.8	474.7	512.4	536.4
Borrowings	0.0	0.0	80.4	82.3	60.6	60.6	60.6	60.6
Other	13.8	13.4	1.3	0.7	0.7	0.7	0.7	0.7
Non current liabilities	13.8	13.4	81.7	83.0	61.3	61.3	61.3	61.3
Total liabilities	319.3	288.1	521.9	462.2	478.1	536.0	573.7	597.7
Net assets	1,134.1	1,084.0	1,194.0	1,149.5	1,256.8	1,320.3	1,389.6	1,449.5
Share capital	146.9	149.1	149.2	0.1	0.1	0.1	0.1	0.1
Reserves	22.9	(110.1)	(136.3)	(177.5)	(224.4)	(224.4)	(224.4)	(224.4)
Retained earnings	964.3	1,044.9	1,167.6	1,323.2	1,490.8	1,564.1	1,641.0	1,708.8
Outside equity Interests	0.0	0.0	13.6	3.7	(9.7)	(19.5)	(27.1)	(34.9)
S/holders' funds	1,134.1	1,084.0	1,194.0	1,149.5	1,256.8	1,320.3	1,389.6	1,449.6
Net Debt (Cash)	(854.2)	(875.2)	(763.0)	(700.7)	(902.7)	(997.7)	(1,083.9)	(1,165.5

i digerpilee (Awpo)								ψ1.20
Shares on issue (m)								724.0
Market cap (A\$m)								5147.8
Enterprise Value (A\$m)								4317.6
Converted at AUDNZD	1.11	EV: MKt c	ap less ca	sh and SM	1 holding			
Year end June	2020	2021	2022	2023	2024	2025e	2026e	2027e
Valuation Ratios								
Adjusted EPS (¢ps)	52.4	10.8	16.4	21.1	23.1	27.5	30.0	30.7
Change (%)	34.5%	-79.3%	51.6%	28.8%	9.2%	19.2%	8.9%	2.4%
Adjusted PE (x)	15.1	72.8	48.0	37.3	34.2	28.6	26.3	25.7
EV/Sales (x)	2.8	4.0	3.3	3.0	2.9	2.5	2.4	2.4
EV/EBITDA (x)	8.7	38.8	24.4	21.8	20.4	17.6	16.1	15.9
EV/EBIT (x)	8.7	41.3	27.0	23.8	23.7	19.8	17.8	17.6
NTA (\$ps)	1.52	1.45	1.59	1.57	1.72	1.81	1.91	1.99
P/NTA (x)	4.7	4.9	4.5	4.5	4.1	3.9	3.7	3.6
Book Value (\$ps)	1.53	1.46	1.61	1.59	1.74	1.82	1.92	2.00
Price/Book (x)	5.1	5.4	4.9	5.0	4.5	4.3	4.1	3.9
DPS (¢)	0.0	0.0	0.0	0.0	0.0	17.5	19.5	21.5
-		0.00/				00 00/		

Performance Ratios								
EBITDA/sales (%)	31.9%	10.2%	13.6%	13.8%	14.0%	14.5%	14.8%	14.8%
EBIT/sales (%)	31.6%	9.6%	12.3%	12.6%	12.1%	12.9%	13.5%	13.4%
OCF Realisation (%)	108%	75%	141%	62%	126%	93%	98%	97%
FCF Realisation (%)	108%	73%	159%	63%	142%	66%	40%	37%
ROE (%)	34.2%	7.4%	10.3%	13.5%	13.3%	15.2%	15.7%	15.4%
ROIC (%)	195.7%	55.5%	41.1%	44.8%	57.1%	75.1%	88.2%	95.7%
Asset turn (years)	125.66	16.56	10.37	12.05	7.28	9.02	10.91	10.31
Capex/Depn (x)	1.64	0.98	0.27	0.57	0.42	0.67	0.75	0.53
Interest cover (x)	(95.31)	(35.25)	(43.22)	(9.24)	(5.62)	(5.63)	(6.96)	(6.54)
Net Debt/EBITDA (x)	(1.55)	(7.09)	(3.89)	(3.20)	(3.85)	(3.66)	(3.65)	(3.87)
Net debt/equity (%)	-75%	-81%	-64%	-61%	-72%	-76%	-78%	-80%

0.0% 0.0% 0.0%

0.0% 0.0% 0.0% 0.0% 0.0% 63.6% 65.0%

0.0%

0.0%

2.5%

2.7%

Segmentals								
Australia/NZ	965.7	559.7	532.7	371.7	317.3	327.1	330.5	334.6
China	699.4	583.4	726.5	1002.2	1143.1	1294.0	1365.2	1396.7
US & UK	66.1	63.6	82.7	105.1	113.7	132.4	151.3	154.5
Processing			108.9	146.2	136.4	166.8	194.5	226.5
Corporate and other	0.0	0.0	(4.5)	(32.3)	(35.0)	(35.0)	(40.0)	(80.0)
Revenue	1,731.1	1,206.7	1,446.2	1,592.9	1,675.5	1,885.3	2,001.6	2,032.2
Australia/NZ	465.6	148.8	173.2	93.5	63.0	55.6	52.3	52.6
China	224.9	75.6	145.1	254.1	290.1	324.5	344.4	344.8
US&UK	(50.5)	(33.5)	(36.7)	(23.3)	(15.5)	(8.4)	(3.4)	2.0
Processing			(18.8)	(26.5)	(20.5)	(14.2)	(9.6)	(9.0)
Corporate & Other	(87.9)	(67.5)	(66.6)	(78.5)	(82.8)	(85.0)	(87.1)	(89.3)
Associates	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	552.0	123.4	196.2	219.3	234.3	272.5	296.7	301.2
Gross Margin (%)	56.0%	42.2%	45.9%	46.4%	45.8%	46.4%	46.3%	46.5%
Marketing (NZ\$m)	194.0	168.7	230.0	260.0	280.1	310.9	330.7	337.7
NZDAUD	0.95	0.93	0.94	0.92	0.93	0.91	0.91	0.91
NZDUSD	0.64	0.70	0.68	0.62	0.61	0.59	0.58	0.58
NZDCNY	4.48	4.57	4.40	4.29	4.38	4.24	4.19	4.20
China PRC label IMF sal	337.7	389.9	437.6	559.3	612.3	627.7	674.9	688.5
China EL IMF sales	341.1	168.9	255.8	386.2	447.8	570.8	601.7	616.6
Other IMF sales	745.1	357.0	328.8	162.5	98.9	90.3	93.4	99.5

SOURCE: BELL POTTER SECURITIES ESTIMATES

#### **Recommendation structure**

Buy: Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected.

Hold: Expect total return between -5% and 15% on a 12 month view

Sell: Expect <-5% total return on a

Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.

Such investments may carry an exceptionally high level of capital risk and volatility of returns.

### **Research Team**

Staff Member	Title/Sector	Phone	@bellpotter.com.au
Chris Savage	Head of Research/Industrials	612 8224 2835	csavage
Rob Crookston	Strategy	612 8224 2813	rcrookston
Paul Basha	Strategy	612 8224 2862	pbasha
Analysts			
John Hester	Healthcare	612 8224 2871	jhester
Martyn Jacobs	Healthcare	613 9235 1683	mjacobs
Thomas Wakim	Healthcare	612 8224 2815	twakim
Michael Ardrey	Industrials	613 9256 8782	mardrey
Marcus Barnard	Industrials	618 9326 7673	mbarnard
Sam Brandwood	Industrials	612 8224 2850	sbrandwood
Joseph House	Industrials	613 9325 1624	jhouse
Baxter Kirk	Industrials	613 9235 1625	bkirk
Daniel Laing	Industrials	612 8224 2886	dlaing
Hayden Nicholson	Industrials	613 9235 1757	hnicholson
Chami Ratnapala	Industrials	612 8224 2845	cratnapala
Jonathan Snape	Industrials	613 9235 1601	jsnape
Connor Eldridge	Real Estate	612 8224 2893	celdridge
Andy MacFarlane	Real Estate	612 8224 2843	amacfarlane
Regan Burrows	Resources	618 9236 7677	rburrows
David Coates	Resources	612 8224 2887	dcoates
Stuart Howe	Resources	613 9325 1856	showe
Brad Watson	Resources	618 9326 7672	bwatson
James Williamson	Resources	613 9235 1692	jwilliamson
Associates			
Brenton Anderson	Associate Analyst	613 9235 1807	banderson
Leo Armati	Associate Analyst	612 8224 2846	larmati
Kion Sapountzis	Associate Analyst	613 9235 1824	ksapountzis
Ritesh Varma	Associate Analyst	613 9235 1658	rvarma

#### **Research Coverage & Policies**

For Bell Potter Securities' Research Coverage Decision Making Process and Research Independence Policy please refer to our company website: https://bellpotter.com.au/research-independence-policy/.

#### Authoring Research Analyst's Certification

The Authoring Research Analyst is responsible for the content of this Research Report, and, certifies that with respect to each security that the Analyst covered in this Report (1) all the views expressed accurately reflect the Analyst's personal views about those securities and were prepared in an independent manner and (2) no part of the Analyst's compensation was, is or will be, directly or indirectly, related to specific recommendations or views expressed by that Research Analyst in the Research Report.

#### **Research Analyst's Compensation**

Research Analyst's compensation is determined by Bell Potter Securities Research Management and Bell Potter Securities' Senior Management and is based upon activities and services intended to benefit the investor clients of Bell Potter Securities Ltd. Compensation is not linked to specific transactions or recommendations. Like all Company employees Research Analysts receive compensation that is impacted by overall Company profitability.

#### Prices

The Price appearing in the Recommendation panel on page 1 of the Research Report is the Closing Price on the Date of the Research Report (appearing in the top right hand corner of page 1 of the Research Report), unless a before midday (am) time appears below the Date of the Research Report in which case the Price appearing in the Recommendation panel will be the Closing Price on the business day prior to the Date of the Research Report.

#### Availability

The completion and first dissemination of a Recommendation made within a Research Report are shortly after the close of the Market on the Date of the Research Report, unless a before midday (am) time appears below the Date of the Research Report in which case the Research Report will be completed and first disseminated shortly after that am time.

#### Dissemination

Bell Potter generally disseminates its Research to the Company's Institutional and Private Clients via both proprietary and non-proprietary electronic distribution platforms. Certain Research may be disseminated only via the Company's proprietary distribution platforms; however such Research will not contain changes to earnings forecasts, target price, investment or risk rating or investment thesis or be otherwise inconsistent with the Author's previously published Research. Certain Research is made available only to institutional investors to satisfy regulatory requirements. Individual Bell Potter Research Analysts may also opt to circulate published Research to one or more Clients by email; such email distribution is discretionary and is done only after the Research has been disseminated. The level and types of service provided by Bell Potter Research Analysts to Clients may vary depending on various factors such as the Client's individual preferences as

### **BELL POTTER**

to frequency and manner of receiving communications from Analysts, the Client's risk profile and investment focus and perspective (e.g. market-wide, sector specific long term and short term etc.) the size and scope of the overall Client relationship with the Company and legal and regulatory constraints.

#### Disclaimers

This Research Report is a private communication to Clients and is not intended for public circulation or for the use of any third party, without the prior written approval of Bell Potter Securities Limited.

The Research Report is for informational purposes only and is not intended as an offer or solicitation for the purpose of sale of a security. Any decision to purchase securities mentioned in the Report must take into account existing public information on such security or any registered prospectus.

This is general investment advice only and does not constitute personal advice to any person. Because this Research Report has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited Broker (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this Research Report.

While this Research Report is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in this document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee expressly or impliedly, that the information contained in this Research Report is complete or accurate.

Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views, opinions or recommendations contained in this Research Report or for correcting any error or omission which may have become apparent after the Research Report has been issued.

Bell Potter Securities Research Department has received assistance from the Company referred to in this Research Report including but not limited to discussions with management of the Company. Bell Potter Securities Policy prohibits Research Analysts sending draft Recommendations, Valuations and Price Targets to subject companies. However, it should be presumed that the Author of the Research Report has had discussions with the subject Company to ensure factual accuracy prior to publication.

All opinions, projections and estimates constitute the judgement of the Author as of the Date of the Research Report and these, plus any other information contained in the Research Report, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice.

Notwithstanding other departments within Bell Potter Securities Limited advising the subject Company, information obtained in such role is not used in the preparation of the Research Report.

Although Bell Potter Research does not set a predetermined frequency for publication, if the Research Report is a fundamental equity research report it is the intention of Bell Potter Research to provide research coverage of the covered issuers, including in response to news affecting the issuer. For non-fundamental Research Reports, Bell Potter Research may not provide regular updates to the views, recommendations and facts included in the reports.

Notwithstanding that Bell Potter maintains coverage on, makes recommendations concerning or discusses issuers, Bell Potter Research may be periodically restricted from referencing certain Issuers due to legal or policy reasons. Where the component of a published trade idea is subject to a restriction, the trade idea will be removed from any list of open trade ideas included in the Research Report. Upon lifting of the restriction, the trade idea will either be re-instated in the open trade ideas list if the Analyst continues to support it or it will be officially closed.

Bell Potter Research may provide different research products and services to different classes of clients (for example based upon longterm or short term investment horizons) that may lead to differing conclusions or recommendations that could impact the price of a security contrary to the recommendations in the alternative Research Report, provided each is consistent with the rating system for each respective Research Report.

Except in so far as liability under any statute cannot be excluded, Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in the document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of the document or any other person.

In the USA and the UK this Research Report is only for institutional investors. It is not for release, publication or distribution in whole or in part in the two specified countries. In Hong Kong this Research Report is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. In the United States this Research Report is being distributed by Bell Potter Securities (US) LLC which is a registered broker-dealer and member of FINRA. Any person receiving this Research Report from Bell Potter Securities (US) LLC and wishing to transact in any security described herein should do so with Bell Potter Securities (US) LLC.

#### Bell Potter Securities Limited ABN 25 006 390 772

Level 29, 101 Collins Street Melbourne, Victoria, 3000 Telephone +61 3 9256 8700 www.bellpotter.com.au

#### Bell Potter Securities (HK) Limited Room 1601, 16/F Prosperity Tower, 39 Queens

Prosperity Tower, 39 Queens Road Central, Hong Kong, 0000 Telephone +852 3750 8400

#### Bell Potter Securities (US) LLC Floor 39 444 Madison Avenue, New York NY 10022, U.S.A Telephone +1 917 819 1410

**Bell Potter Securities (UK) Limited** 16 Berkeley Street London, England W1J 8DZ, United Kingdom Telephone +44 7734 2929

# **BÉLL POTTER**